Swiss Medica Inc., Innovative Products That Improve Peoples' Lives

12/16/2004 9:33:01 AM ET

SWISS MEDICA BOOSTS RETAIL STORE COVERAGE OF O24 PRODUCT PAST 1,600 MILESTONE

FOR IMMEDIATE RELEASE

Stock Symbol: OTC BB: SWME

December 16, 2004

SWISS MEDICA BOOSTS RETAIL STORE COVERAGE OF O24 PRODUCT PAST 1,600 MILESTONE

Toronto, Canada – Swiss Medica’s marketing efforts during the fourth quarter boosted the number of retail

stores, which carry the O24™ Essential Oil Pain Neutralizer, above the 1,600 milestone – an increase of 46%

during the past two months.

“Our sales and marketing team was extremely busy throughout the fourth quarter, increasing the quantity of

retailers that offer the O24™ pain relief product,” said Chief Executive Officer, Raghu Kilambi. “The marketing

team effectively promoted the Company’s flagship product to larger, different and a greater quantity of

audiences, which is reflected in our website and phone traffic, and the number of re-orders from our commercial

customers.”

About Swiss Medica Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our

market share through focused distribution strategies in multiple sales channels. Swiss Medica’s mission is to be

a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please

visit our websites at www.swissmedica.com and

Swiss Medica’s flagship product, the 024™ Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The

024™ pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits

by healthcare professionals in the United States, Canada and in Europe. O24 is widely available throughout

Canada in leading pharmacies and natural food stores. It is available in the United States and elsewhere by

visiting

, for ordering details and store locators.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the

United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking

statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close

transactions being contemplated, risks related to international sales and potential foreign currency exchange

fluctuations, continued acceptance of Swiss Medica’s products, increased levels of competition, technological

changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica’s

periodic reports filed with the United States Securities and Exchange Commission and other regulatory

authorities.

Investor Relations Contact:

David Jones

Swiss Medica Inc.

1 866 485 4243